214 related articles for article (PubMed ID: 7916020)
1. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
Abelson MB; George MA; Schaefer K; Smith LM
J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
[TBL] [Abstract][Full Text] [Related]
2. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model.
Abelson MB; George MA; Smith LM
Ophthalmology; 1995 Feb; 102(2):310-6. PubMed ID: 7862419
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of levocabastine in conjunctival provocation studies.
Janssens M
Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
[TBL] [Abstract][Full Text] [Related]
12. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
Secchi A; Leonardi A; Discepola M; Deschenes J; Abelson MB
Acta Ophthalmol Scand Suppl; 2000; (230):48-51. PubMed ID: 11057351
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
Richard C; Bibas P; Lablache-Combier M; Allaire C
J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
15. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
16. New trends in the treatment of allergic conjunctivitis.
Parys W; Blockhuys S; Janssens M
Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981
[TBL] [Abstract][Full Text] [Related]
17. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
Abelson MB; Lanier RQ
Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
[TBL] [Abstract][Full Text] [Related]
18. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
19. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis.
Stokes TC; Feinberg G
Clin Exp Allergy; 1993 Sep; 23(9):791-4. PubMed ID: 10779311
[TBL] [Abstract][Full Text] [Related]
20. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
Richard C; Trinquand C; Bloch-Michel E
Eur J Ophthalmol; 1998; 8(4):207-16. PubMed ID: 9891891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
